
Jerome Doyen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9405739/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial. Clinical Lung Cancer, 2022, 23, e252-e256.	2.6	10
2	Intensityâ€modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Costâ€effectiveness analysis. Head and Neck, 2022, 44, 431-442.	2.0	3
3	Propensity score analysis of radical proctectomy versus organ preservation using contact X-ray brachytherapy for rectal cancer. Clinical and Translational Radiation Oncology, 2022, 33, 70-76.	1.7	2
4	Current practice in proton therapy delivery in adult cancer patients across Europe. Radiotherapy and Oncology, 2022, 167, 7-13.	0.6	23
5	Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma. Cancers, 2022, 14, 70.	3.7	7
6	Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse. Clinical Oncology, 2021, 33, e15-e21.	1.4	2
7	Contact X-ray brachytherapy for rectal cancer: Past, present, and future. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 795-800.	1.4	7
8	Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients. , 2021, 9, e002512.		8
9	Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness. BMC Cancer, 2021, 21, 944.	2.6	3
10	Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factors. Radiotherapy and Oncology, 2021, 161, 198-204.	0.6	2
11	Postsurgical geometrical variations of tumor bed and brainstem during photon and proton therapy for pediatric tumors of the posterior fossa: dosimetric impact and predictive factors. Strahlentherapie Und Onkologie, 2021, 197, 1113-1123.	2.0	3
12	Present and Future Research on Anal Squamous Cell Carcinoma. Cancers, 2021, 13, 3895.	3.7	12
13	Role of proton therapy in reirradiation and in the treatment of sarcomas. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 550-553.	1.4	2
14	Fractionated Stereotactic Radiation Therapy for Pituitary Adenomas: An alternative escalating protocol of hypofractionated stereotactic radiotherapy delivering 35 Gy in 5 fractions. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, , .	1.4	2
15	RGD-functionalized magnetosomes are efficient tumor radioenhancers for X-rays and protons. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 23, 102084.	3.3	15
16	Radiotherapy for primary tumor in lung cancer with synchronous metastases: Overview from the past and proposal for the future. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 554-558.	1.4	1
17	VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. Communications Biology, 2020, 3, 579.	4.4	9
18	A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. Clinical Cancer Research, 2020, 26, 5198-5207.	7.0	66

JEROME DOYEN

#	Article	IF	CITATIONS
19	Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bulletin Du Cancer, 2020, 107, 946-958.	1.6	15
20	Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China. BMC Cancer, 2020, 20, 599.	2.6	12
21	A brief history of contact X-ray brachytherapy 50ÂkVp. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 222-225.	1.4	10
22	Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments. Frontiers in Oncology, 2020, 10, 613089.	2.8	4
23	Outcome and Patterns of Relapse in Childhood Parameningeal Rhabdomyosarcoma Treated With Proton Beam Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1043-1054.	0.8	21
24	In Reply to Gultekin and Yildiz. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1164-1165.	0.8	0
25	Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study. European Journal of Cancer, 2019, 108, 1-16.	2.8	49
26	Patterns of proton therapy use in pediatric cancer management in 2016: An international survey. Radiotherapy and Oncology, 2019, 132, 155-161.	0.6	42
27	Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial. Radiotherapy and Oncology, 2018, 127, 239-245.	0.6	5
28	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. Critical Reviews in Oncology/Hematology, 2018, 125, 41-47.	4.4	32
29	Accelerated partial breast irradiation for suitable elderly women using a single fraction of multicatheter interstitial high-dose-rate brachytherapy: Early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase I/II trial. Brachytherapy, 2018, 17, 407-414.	0.5	31
30	Changes in Ocular Subfoveal Choroidal Thickness After Carotid Endarterectomy Using Enhanced Depth Imaging Optical Coherence Tomography: A Pilot Study. Angiology, 2018, 69, 574-581.	1.8	17
31	Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials. Cancer Treatment Reviews, 2018, 70, 265-271.	7.7	43
32	Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients. European Journal of Cancer, 2017, 72, 124-136.	2.8	36
33	Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. Diseases of the Colon and Rectum, 2017, 60, 785-791.	1.3	25
34	Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Annals of Oncology, 2017, 28, 2436-2442.	1.2	72
35	Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy. JAMA Dermatology, 2017, 153, 1056.	4.1	13
36	Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma. Oncogenesis, 2017, 6, e354-e354.	4.9	49

JEROME DOYEN

#	Article	IF	CITATIONS
37	Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy. Clinical Colorectal Cancer, 2017, 16, e211-e220.	2.3	33
38	Immunotherapy for rectal carcinoma: Some stimulating data but still a long way to clinical evidence. European Journal of Cancer, 2016, 68, 70-72.	2.8	0
39	Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. Cancer Treatment Reviews, 2016, 43, 104-112.	7.7	69
40	Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid type fibromatosis lesions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 369-374.	2.8	13
41	New Neoadjuvant Treatment Strategies for Non-Metastatic Rectal Cancer (M0). Current Colorectal Cancer Reports, 2015, 11, 289-297.	0.5	0
42	Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud – Nice experience using contact x-ray brachytherapy and external beam radiotherapy for 120 patients. Acta Oncológica, 2015, 54, 550-556.	1.8	30
43	Results of age-dependent anal canal cancer treatment: A single centre retrospective study. Digestive and Liver Disease, 2014, 46, 460-464.	0.9	14
44	Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochemical and Biophysical Research Communications, 2014, 451, 54-61.	2.1	95
45	Magnetic resonance guided focalised ultrasound thermo-ablation: A promising oncologic local therapy. Diagnostic and Interventional Imaging, 2014, 95, 339-343.	3.2	4
46	Aims of Combined Modality Therapy in Rectal Cancer (M0). Recent Results in Cancer Research, 2014, 203, 153-169.	1.8	14
47	Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer. Oncotarget, 2014, 5, 8123-8135.	1.8	20
48	Predictive Factors for Early and Late Local Toxicities in Anal Cancer Treated by Radiotherapy in Combination With or Without Chemotherapy. Diseases of the Colon and Rectum, 2013, 56, 1125-1133.	1.3	18
49	Conjunctival melanomas and proton beam therapy. Acta Ophthalmologica, 2013, 91, e647-e647.	1.1	10
50	Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis. Frontiers in Oncology, 2013, 2, 199.	2.8	61
51	<i><scp>EGFR</scp></i> , <i><scp>KRAS</scp></i> , <i><scp>BRAF</scp></i> , and <i><scp>HER</scp>â€2</i> molecular status in brain metastases from 77 <scp>NSCLC</scp> patients. Cancer Medicine, 2013, 2, 296-304.	2.8	32
52	MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death and Disease, 2013, 4, e544-e544.	6.3	192
53	Renal cell carcinoma and a constitutional t(11;22)(q23;q11.2): case report and review of the potential link between the constitutional t(11;22) and cancer. Cancer Genetics, 2012, 205, 603-607.	0.4	4
54	Towards a "Lyon molecular signature―to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94Ârectal cancers T1-2-3 Nx MO to be the basis of a molecular signature. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2012, 16, 688-696.	1.4	2

JEROME DOYEN

#	Article	IF	CITATIONS
55	Circulating tumor cells in prostate cancer: A potential surrogate marker of survival. Critical Reviews in Oncology/Hematology, 2012, 81, 241-256.	4.4	68
56	CÅ"ur et radiations ionisantesÂ: les complications aiguës et tardives à ne pas méconnaître. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2011, 2011, 7-11.	0.0	1
57	Aromatase inhibition in male breast cancer patients: biological and clinical implications. Annals of Oncology, 2010, 21, 1243-1245.	1.2	76
58	Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia. British Journal of Haematology, 2008, 141, 744-745.	2.5	5
59	Prognostic factors in 1038 women with metastatic breast cancer. Annals of Oncology, 2008, 19, 2012-2019.	1.2	301